Product Details
Synonyms
CD40, Bp50, CDW40, MGC9013, TNFRSF5, p50
Source
Human CD40 Protein, Mouse IgG2a Fc Tag (CD0-H525a) is expressed from human 293 cells (HEK293). It contains AA Glu 21 - Arg 193 (Accession # P25942-1).
Predicted N-terminus: Glu 21
Request for sequenceMolecular Characterization

Other Tags and Version Biotin & Other Labeled Version
This protein carries a mouse IgG2a Fc tag at the C-terminus.
The protein has a calculated MW of 46.1 kDa. The protein migrates as 58 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.
Endotoxin
Less than 0.01 EU per μg by the LAL method / rFC method.
Purity
>95% as determined by SDS-PAGE.
>95% as determined by SEC-MALS.
Formulation
Lyophilized from 0.22 μm filtered solution in 50 mM Tris, 100 mM Glycine, 150 mM NaCl, pH7.5 with trehalose as protectant.
Contact us for customized product form or formulation.
Reconstitution
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
Shipping and Storage
This product is shipped at ambient temperature.
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
- -20°C to -70°C for 12 months in lyophilized state;
- -70°C for 3 months under sterile conditions after reconstitution.
ACRO Quality Management System
Customers Also Viewed
Performance Data
SDS-PAGE

Human CD40 Protein, Mouse IgG2a Fc Tag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95%.
SEC-MALS

The purity of Human CD40 Protein, Mouse IgG2a Fc Tag (Cat. No. CD0-H525a) is more than 95% and the molecular weight of this protein is around 110-125 kDa verified by SEC-MALS.
Report
Bioactivity-ELISA

Immobilized Human CD40 Ligand, His,Flag Tag, premium grade (Cat. No. CDL-H52Db) at 5 μg/mL (100 μL/well) can bind Human CD40 Protein, Mouse IgG2a Fc Tag (Cat. No. CD0-H525a) with a linear range of 0.01-0.3 μg/mL (QC tested).
Protocol
Bioactivity-BLI

Loaded Human CD40 Protein, Mouse IgG2a Fc Tag (Cat. No. CD0-H525a) on Protein A Biosensor, can bind Human CD40 Ligand, His,Flag Tag, premium grade (Cat. No. CDL-H52Db) with an affinity constant of 0.911 nM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).
Protocol
Bioactivity-Flow Cytometry

FACS analysis shows that Human CD40 Protein, Mouse IgG2a Fc Tag (Cat. No. CD0-H525a) can bind to 293T cells overexpressing human CD40L. The concentration of Human CD40 is 0.03 μg/ml (Routinely tested).
Protocol
Customer Reviews Writing Reviews

FAQ
- product
Can lyophilized proteins remain stable during room-temperature shipping or temporary room-temperature exposure?
In general, lyophilized proteins remain stable during room-temperature shipping or temporary exposure to room-temperature conditions.
Many ACROBiosystems recombinant proteins are supplied in lyophilized (freeze-dried) form. The lyophilization process effectively removes moisture from the product, helping reduce degradation-related reactions and improve protein stability during transportation and storage.
To evaluate the stability of lyophilized proteins under normal temperature conditions, ACROBiosystems conducted a stability study on 11 representative lyophilized protein products at 37°C. The study demonstrated that these proteins maintained good quality stability after storage at 37°C for approximately 20 days. Based on these validation results, temporary room-temperature exposure during shipping or handling is generally not expected to have a significant impact on product quality or downstream application performance.
To ensure optimal long-term stability, products should be stored according to the storage conditions specified in the product Certificate of Analysis (COA) upon receipt.
Supporting Document
Background
Recent Advances
- English Name:
Tumor necrosis factor receptor superfamily member 5
- Category:
- Approved Drugs:
0 Details
- Drugs in Clinical Trials:
46 Details
- Highest Development Stage:
Phase 3 Clinical
[North America]: +1 800-810-0816
[Switzerland]: +41 800 040 012
[Asia & Pacific]: +86 400-682-2521



















